Cargando…

A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) presents with disabling symptoms and may lead to insufficient growth and late pubertal development in cases of disease onset during childhood or adolescence. During the last decade, the role of anti-tumor necrosis factor (TNF) in the treatment of paediatric-onset IBD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aardoom, Martine A., Veereman, Gigi, de Ridder, Lissy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566820/ https://www.ncbi.nlm.nih.gov/pubmed/31126015 http://dx.doi.org/10.3390/ijms20102529

Ejemplares similares

International prospective observational study investigating the disease course and heterogeneity of paediatric-onset inflammatory bowel disease: the protocol of the PIBD-SETQuality inception cohort study
por: Aardoom, Martine A, et al.
Publicado: (2020)

The Incidence and Characteristics of Venous Thromboembolisms in Paediatric-Onset Inflammatory Bowel Disease: A Prospective International Cohort Study Based on the PIBD-SETQuality Safety Registry
por: Aardoom, Martine A, et al.
Publicado: (2021)

Anti-TNF Withdrawal in Inflammatory Bowel Disease
por: Torres, Joana, et al.
Publicado: (2016)

Self‐efficacy did not predict the outcome of the transition to adult care in adolescents with inflammatory bowel disease
por: van den Brink, Gertrude, et al.
Publicado: (2018)

Venous Thromboembolic Complications in Pediatric Gastrointestinal Diseases: Inflammatory Bowel Disease and Intestinal Failure
por: Klomberg, Renz C. W., et al.
Publicado: (2022)

Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease
por: Schneider, Anna-Maria, et al.
Publicado: (2018)

The Continental Divide: Anti-TNF Use in Pediatric IBD Is Different in North America Compared to Other Parts of the World
por: Church, Peter C., et al.
Publicado: (2018)

Paediatric Inflammatory Bowel Disease: A Multi-Stakeholder Perspective to Improve Development of Drugs for Children and Adolescents
por: Croft, Nicholas M, et al.
Publicado: (2022)

Identifying Health Economic Considerations to Include in the Research Protocol of a Randomized Controlled Trial (the REDUCE-RISK Trial): Systematic Literature Review and Assessment
por: Neyt, Mattias, et al.
Publicado: (2021)

Anti‐TNF‐induced lupus in patients with inflammatory bowel disease
por: Picardo, Sherman, et al.
Publicado: (2019)

Health Care Transition Outcomes in Inflammatory Bowel Disease: A Multinational Delphi Study
por: van den Brink, Gertrude, et al.
Publicado: (2019)

Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn’s disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course
por: Harris, Rachel E, et al.
Publicado: (2020)

Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF
por: Cachen, Laurie, et al.
Publicado: (2022)

Systematic review: genetic biomarkers associated with anti‐TNF treatment response in inflammatory bowel diseases
por: Bek, S., et al.
Publicado: (2016)

Inflammatory Bowel Disease as a Paradoxical Reaction to Anti-TNF-α Treatment—A Review
por: Mihai, Ioana Ruxandra, et al.
Publicado: (2023)

Pott’s Puffy Tumor in an Inflammatory Bowel Disease Patient on Anti-TNF Therapy
por: Miri, Ahmad, et al.
Publicado: (2021)

Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease
por: Orfanoudaki, Eleni, et al.
Publicado: (2023)

IgA Nephropathy in the Setting of Anti-TNF-α Therapy for Inflammatory Bowel Disease
por: Strobel, Thomas, et al.
Publicado: (2020)

Fatigue in children and adolescents with inflammatory bowel disease
por: Van de Vijver, Els, et al.
Publicado: (2019)

Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
por: Salvador-Martín, Sara, et al.
Publicado: (2020)

Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
por: Salvador-Martín, Sara, et al.
Publicado: (2021)

A guide to preparation of patients with inflammatory bowel diseases for anti-TNF-α therapy
por: Chebli, Júlio Maria Fonseca, et al.
Publicado: (2014)

Investigation of the effects of anti-TNF agents on hemoglobin levels in patients with inflammatory bowel disease
por: Okuyucu, Muhammed, et al.
Publicado: (2022)

Inflammatory Bowel Disease in Australasian Children and Adolescents
por: Day, A. S., et al.
Publicado: (2014)

Ultrasound in children and adolescents with inflammatory bowel disease
por: La Seta, Francesco, et al.
Publicado: (2014)

Leishmania infantum asymptomatic infection in inflammatory bowel disease patients under anti-TNF therapy
por: Guillén, M. Carmen, et al.
Publicado: (2020)

Anti-TNF therapy for inflammatory bowel disease in patients with neurodegenerative Niemann-Pick disease Type C
por: Williams, Isabelle, et al.
Publicado: (2022)

Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis
por: Guberna, Laura, et al.
Publicado: (2021)

Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review
por: Marquez-Megias, Silvia, et al.
Publicado: (2022)

Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?
por: Gisbert, Javier P., et al.
Publicado: (2021)

Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?
por: Eun, Chang Soo
Publicado: (2017)

Anti-TNF-α Therapy Suppresses Proinflammatory Activities of Mucosal Neutrophils in Inflammatory Bowel Disease
por: Zhang, Cui, et al.
Publicado: (2018)

Potential Impact of Diet on Treatment Effect from Anti-TNF Drugs in Inflammatory Bowel Disease
por: Andersen, Vibeke, et al.
Publicado: (2017)

Risk of Lymphoma Associated with Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: Implications for Therapy
por: Dahmus, Jessica, et al.
Publicado: (2020)

Mucosal gene expression changes induced by anti‐TNF treatment in inflammatory bowel disease patients
por: Milanesi, Elena, et al.
Publicado: (2019)

Specific T-Cell Subsets Can Predict the Efficacy of Anti-TNF Treatment in Inflammatory Bowel Diseases
por: Dulic, Sonja, et al.
Publicado: (2020)

Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers
por: Cui, Guanglin, et al.
Publicado: (2021)

Serum Levels of Chemerin in Patients with Inflammatory Bowel Disease as an Indicator of Anti-TNF Treatment Efficacy
por: Sochal, Marcin, et al.
Publicado: (2021)

NAMPT and NAPRT serum levels predict response to anti-TNF therapy in inflammatory bowel disease
por: Colombo, Giorgia, et al.
Publicado: (2023)

Nutritional impact of inflammatory bowel diseases on children and adolescents
por: dos Santos, Gilton Marques, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_cjv60vhfl6gj2dq2q87ot2plpk